Zu lab Publications


B7-H4 expression in ovarian serous carcinoma: a study of 306 cases
Liang, L, Jiang, Y, Chen, JS, Niu, N, Piao, J, Ning, J, Zu, Y, Zhang, J & Liu, J 2016, Human Pathology, vol 57, pp. 1-6. DOI:

Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma
Xu-Monette, ZY, Deng, Q, Manyam, GC, Tzankov, A, Li, L, Xia, Y, Wang, XX, Zou, D, Visco, C, Dybkær, K, Li, J, Zhang, L, Liang, H, Montes-Moreno, S, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Wang, SA, Miranda, RN, Piris, MA, Winter, JN, Medeiros, LJ, Li, Y & Young, KH 2016, Clinical Cancer Research, vol 22, no. 14, pp. 3593-3605. DOI:

Aptamers: Versatile molecular recognition probes for cancer detection
Sun, H, Tan, W & Zu, Y 2016, Analyst, vol 141, no. 2, pp. 403-415. DOI:

SsDNA aptamer specifically targets and selectively delivers cytotoxic drug doxorubicin to HepG2 Cells
Yu, G, Li, H, Yang, S, Wen, J, Niu, J & Zu, Y 2016, PLoS ONE, vol 11, no. 1, e0147674. DOI:

p63 expression confers significantly better survival outcomes in highrisk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function
Xu-Monette, ZY, Zhang, S, Li, X, Manyam, GC, Wang, XX, Xia, Y, Visco, C, Tzankov, A, Zhang, L, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, HJ, Huh, J, Ponzoni, M, Ferreri, AJM, Zhao, X, Møller, MB, Parsons, BM, Winter, JN, Piris, MA, Medeiros, JL & Young, KH 2016, Aging, vol 8, no. 2, pp. 345-365.

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
Ye, Q, Xu-Monette, ZY, Tzankov, A, Deng, L, Wang, X, Manyam, GC, Visco, C, Montes-Moreno, S, Zhang, L, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Piris, MA, Winter, JN, Medeiros, LJ, Hu, VDS & Young, KH 2016, Oncotarget, vol 7, no. 3, pp. 2401-2416. DOI:

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Xu-Monette, ZY, Dabaja, BS, Wang, X, Tu, M, Manyam, GC, Tzankov, A, Xia, Y, Zhang, L, Sun, R, Visco, C, Dybkaer, K, Yin, L, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Parsons, BM, Zhao, X, Winter, JN, Piris, MA, McDonnell, TJ, Miranda, RN, Li, Y, Medeiros, LJ & Young, KH 2015, Modern Pathology, vol 28, no. 12, pp. 1555-1573. DOI:

Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy
Liu, Z, Xu-Monette, ZY, Cao, X, Manyam, GC, Wang, X, Tzankov, A, Xia, Y, Li, X, Visco, C, Sun, R, Zhang, L, Montes-Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Møller, MB, Piris, MA, Winter, JN, OMalley, DP, Medeiros, LJ & Young, KH 2015, Modern Pathology, vol 28, no. 10, pp. 1297-1314. DOI:

Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia
Zhao, N, Pei, SN, Qi, J, Zeng, Z, Iyer, SP, Lin, P, Tung, CH & Zu, Y 2015, Biomaterials, vol 67, pp. 42-51. DOI:

Evaluation of NF-?B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions
Ok, CY, Xu-Monette, ZY, Li, L, Manyam, GC, Montes-Moreno, S, Tzankov, A, Visco, C, Dybkær, K, Routbort, MJ, Zhang, L, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Parsons, BM, Rao, H, Møller, MB, Winter, JN, Piris, MA, Wang, SA, Medeiros, LJ & Young, KH 2015, Modern Pathology, vol 28, no. 9, pp. 1202-1213. DOI:

A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
Wen, J, Tao, W, Hao, S, Iyer, SP & Zu, Y 2016, Leukemia, vol 30, no. 4, pp. 987-91. DOI:

CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation
Han, X, Liu, Z, Jo, MC, Zhang, K, Li, Y, Zeng, Z, Li, N, Zu, Y & Qin, L 2015, Science advances, vol 1, no. 7, pp. e1500454. DOI:

A Highlight of recent advances in aptamer technology and its application
Sun, H & Zu, Y 2015, Molecules, vol 20, no. 7, pp. 11959-11980. DOI:

Pre-clinical efficacy of combined therapy with novel ß-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells
Fiskus, W, Sharma, S, Saha, S, Shah, B, Devaraj, SGT, Sun, B, Horrigan, S, Leveque, C, Zu, Y, Iyer, S & Bhalla, KN 2015, Leukemia, vol 29, no. 6, pp. 1267-1278. DOI:

Aptamers and their applications in nanomedicine
Sun, H & Zu, Y 2015, Small, vol 11, no. 20, pp. 2352-2364. DOI:

Mutated genes and driver pathways involved in myelodysplastic syndromes - a transcriptome sequencing based approach
Liu, L, Wang, H, Wen, J, Tseng, CE, Zu, Y, Chang, CC & Zhou, X 2015, Molecular BioSystems, vol 11, no. 8, pp. 2158-2166. DOI:

Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma
Li, L, Xu-Monette, ZY, Ok, CY, Tzankov, A, Manyam, GC, Sun, R, Visco, C, Zhang, M, Montes-Moreno, S, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Møller, MB, Wang, J, Parsons, BM, Winter, JN, Piris, MA, Pham, LV, Jeffrey Medeiros, L & Young, KH 2015, Oncotarget, vol 6, no. 27, pp. 23157-23180. DOI:

Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
Chen, J, Xu-Monette, ZY, Deng, L, Shen, Q, Manyam, GC, Martinez-Lopez, A, Zhang, L, Montes-Moreno, S, Visco, C, Tzankov, A, Yin, L, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, Han van Krieken, J, Huh, J, Ponzoni, M, Ferreri, AJM, Zhao, X, Møller, MB, Farnen, JP, Winter, JN, Piris, MA, Pham, L & Young, KH 2015, Oncotarget, vol 6, no. 8, pp. 5597-5614.

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?
Ok, CY, Ye, Q, Li, L, Manyam, GC, Deng, L, Goswami, RR, Wang, X, Montes-Moreno, S, Visco, C, Tzankov, A, Dybkaer, K, Zhang, L, Abramson, J, Sohani, AR, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Zhang, S, Parsons, BM, Xu, M, Møller, MB, Winter, JN, Piris, MA, Xu-Monette, ZY, Medeiros, LJ & Young, KH 2015, Oncotarget, vol 6, no. 16, pp. 13933-13945. DOI:

Erratum to Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries [Oncotarget, 8, (2015), 5615-5633]
Xu-Monette, ZY, Tu, M, Jabbar, KJ, Cao, X, Tzankov, A, Visco, C, Nagarajan, L, Cai, Q, Montes-Moreno, S, An, Y, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Zhao, X, Møller, MB, Farnen, JP, Winter, JN, Piris, MA, Miranda, RN, Medeiros, LJ & Young, KH 2015, Oncotarget, vol 6, no. 16, pp. 14720.